193 Edoxaban versus warfarin on stroke risk in patients with atrial fibrillation: a territory-wide cohort study. (4th June 2021)

• Record Type: Journal Article
• Authors: Kong, Che Him Dicken; Zhou, Jiandong; Lee, Sharen; Leung, Keith Sai Kit; Liu, Tong; Sawant, Abhishek C; Corbelli, John; Wai, Abraham KC; Chang, Carlin; Zhang, Qingpeng; Tse, Gary
• Is Part Of: Heart. Volume 107(2021)Supplement 1
• Page Start: A149
• Page End: A150
• Publication Date: 2021-06-04
• Subjects: atrial fibrillation -- stroke -- edoxaban; Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heartjnl-2021-BCS.189
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Background: In this territory-wide, observational, propensity score-matched cohort study, we evaluate the development of transient ischaemic attack and ischaemic stroke (TIA/Ischaemic stroke) in patients with AF treated with edoxaban or warfarin. Methods: This was an observational, territory-wide cohort study of patients between January 1st, 2016 and December 31st, 2019, in Hong Kong. The inclusion were patients with i) atrial fibrillation, and ii) edoxaban or warfarin prescription. 1:2 propensity score matching was performed between edoxaban and warfarin users. Univariate Cox regression identifies significant risk predictors of the primary, secondary and safety outcomes. Hazard ratios (HRs) with corresponding 95% confidence interval [CI] and p values were reported. Results: This cohort included 3464 patients (54.18% males, median baseline age: 72 years old, IQR: 63-80, max: 100 years old), 664 (19.17%) with edoxaban use and 2800 (80.83%) with warfarin use. ( Figure 1 ) . After a median follow-up of 606 days (IQR: 306-1044, max: 1520 days), 91(incidence rate: 2.62%) developed TIA/ischaemic stroke: 1.51% (10/664) in the edoxaban group and 2.89% (81/2800) in the warfarin group. Edoxaban was associated with a lower risk of TIA or ischemic stroke when compared to warfarin ( figure 2 ) . Conclusions: Edoxaban use was associated with a lower risk of TIA or ischemic stroke after propensity score matching for demographics, comorbidities and medication use. Conflict of Interest: None